Key Points Moderna may look appealing right now, given the company's high cash balance and extensive drug pipeline. However, as Moderna's cash burn dilemma persists, the company's net value will likely keep declining. For now, it's best to assume that shares will continue to slowly, but steadily, drop in value. 10 stocks we like better than Moderna › Has Moderna (NASDAQ: MRNA) finally bottomed out? You may be asking that yourself right now, as shares in the biotech company have held steady at aro ...